Troponin and Copeptin assay
Diagnostic TestCollection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
NCT Number: NCT05902117
The aim of this study is to demonstrate that a combined troponin and copeptin assay can exclude non-ST+ ACS in patients with chest pain less than 6 hours old.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Emergency Department (SAMU) Hospital NOVO - Pontoise site, Pontoise, France
Chest pain accounts for about 10% of emergency service visits, which represents between 6 and 8 million visits per year in the United States and 15 million in Europe. Depending on the series, coronary etiology is found in 10 to 50% of cases.
Two types of coronary syndrome are distinguished according to the existence of a pathological change in the electrocardiogram.
ST+ acute coronary syndrome is a diagnosis based on the association of chest pain associated with an electrocardiogram change in the form of ST-segment elevation in a systemic territory corresponding to the complete obstruction of an artery of the coronary network.
Non-ST+ coronary syndrome is more difficult to diagnose, as the ECG is not pathological or cannot be interpreted due to the presence of conduction disorders. The diagnosis is currently based on the pathological increase of a specific myocardial biomarker in the blood: troponin.
If the pain is recent (less than six hours) the troponin measured on arrival may be falsely negative, and therefore requires a second measurement 3 hours after the first one (this is the troponin cycle). This second test therefore leads to a longer stay for patients requiring it and contributes to the saturation of the emergency service.
Copeptin is an endogenous stress biomarker that rises immediately during a myocardial infarction and decreases rapidly. Unlike troponin, this marker is not myocardial specific and its level can rise in the blood for many reasons, which is why this marker cannot be used alone in the diagnosis of non-ST+ acute coronary syndrome (non-ST+ ACS or ST- ACS).
The hypothesis would be that the association of a copeptin assay with the initial troponin assay could, if both markers are below pathological thresholds (Troponin < 16ng.dL), eliminate the diagnosis of acute coronary syndrome from the first assays and thus avoid the second troponin assay 3 hours after the first. The patient would reduce the time spent in the emergency and would thus reduce the number of patients in the emergency service.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non -Inclusion Criteria:
Exclusion criteria
Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
Time frame: At the end of the study, an average of 8 month
Comparison of copeptin and troponin assays in the final diagnosis of non-ST+ ACS based on emergency medical records by calculation the sensitivity/specificity of the troponin - copeptin pair.
Time frame: At the end of the study, an average of 8 month
Comparison of copeptin and troponin assays in the final diagnosis of non-ST+ ACS based on emergency medical records by calculation of the negative predictive value of the troponin - copeptin pair.
Time frame: At the end of the study, an average of 8 month
Evaluation of the diagnostic performance (sensitivity/specificity) of the troponin - copeptin pair for each subgroup of cardiovascular risk factors (age / smoking / hypertension / history of cardiac ischemia / overweight and heredity).
Time frame: At the end of the study, an average of 8 month
Evaluation of the diagnostic performance (negative predictive value) of the troponin - copeptin pair for each subgroup of cardiovascular risk factors (age / smoking / hypertension / history of cardiac ischemia / overweight and heredity).
Time frame: At the end of the Study, an average of 8 month
Collection of the number of days or hours spent in the emergency service from the time of arrival
Time frame: At the end of the study, an average of 8 month
The diagnostic performance of the troponin/ copeptin combination is evaluated according to the time between the first pain and blood sampling
Time frame: At the end of the study, an average of 8 month
Assessment of the evolution of pain via the numerical scale (EN), rated from 0 to 10, between arrival in the emergency room and reassessment at 3 hours
Hôpital NOVO
Other
Place of Copeptin-troponin Assay in the Elimination Diagnosis of Non-ST+ ACS in the Management of Pre-hospital and In-hospital Non-traumatic Chest Pain in Adults
Acronym: CopSCA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05853042
Acute Coronary Syndrome, Acute Myocardial Infarction
Minneapolis, Minnesota, United States
View Trial DetailsNCT06457815
Acute Myocardial Infarction
Middlesbrough, Teesside, United Kingdom
View Trial DetailsNCT04938661
Acute Coronary Syndrome, Acute Myocardial Infarction
Minneapolis, Minnesota, United States
View Trial DetailsNCT05149560
Acute Myocardial Infarction
Gothenburg, Sweden
View Trial Details